Multiple sclerosis (MS) is a central nervous system inflammatory disorder with evidence of peripheral immune dysregulation. Abnormalities of the immune suppressive cytokine TGF-β have been reported, but not fully defined, in MS. Through a pathway-focused expression profiling of the peripheral blood, we found abnormalities of TGF-βRII, SMAD4 and SMAD7 expression in subjects with MS, and reduction in the levels of TGF-β regulated genes, indicating an overall reduction in TGF-β signaling in MS. The response to exogenous TGF-β was intact, however, indicating an extrinsic defect of TGF-β signaling in MS. These results indicate that TGF-β control is diminished in MS.
Introduction
Multiple sclerosis (MS) is a chronic disabling inflammatory disease of the central nervous system, where the presence of activated autoreactive T cells in the periphery suggests that defects in immune regulation may contribute to the pathogenesis (Zhang et al., 1994) . Transforming growth factor-β (TGF-β) is a pleiotropic cytokine with immune regulatory properties (Gorelik and Flavell, 2002) . TGF-β plays a key role in suppressing autoreactive T cell responses, either as a soluble mediator of immune suppression or as a membrane-bound effector molecule of CD4 + CD25
+ regulatory T cells (Nakamura et al., 2001 ). Abnormalities of TGF-β production have been reported in MS, but the results are conflicting and as yet unresolved (Mokhtarian et al., 1994; Correale et al., 1995; Monteyne et al., 1998; Link et al., 1994) . More recently, gene expression profiling studies of MS have identified altered expression of the TGF-β-regulated gene SMAD7 (Achiron et al., 2004; Bomprezzi et al., 2003) , suggesting that abnormalities of TGF-β signaling are detectable at the transcriptional level and may be informative in understanding the role of TGF-β in MS.
The integrity of the TGF-β signaling pathway in MS has yet to be fully characterized. TGF-β exerts its immune suppressive properties through the SMAD signaling cascade (Shi and Massague, 2003) . Upon binding of TGF-β to its receptor, composed of TGF-βRI and TGF-βRII subunits, receptor-regulated SMAD2 and SMAD3 are recruited and phosphorylated. The SMAD2/3 heterodimer then complexes with the commonmediator SMAD4, leading to nuclear translocation where the SMAD complex controls the transcriptional activity of a number of downstream target genes including the inhibitory SMAD7, platelet activating inhibitor, and cyclin dependent kinase inhibitor p21 (Datto et al., 1995) .
To assess the integrity of the TGF-β signaling pathway in MS, we compared peripheral blood mononuclear cells (PBMC) from subjects with MS and healthy donors by TGF-β pathway-focused expression profiling, and by assessing TGF-β signaling capacity.
Materials and methods

Samples
Blood samples were collected from 25 subjects with untreated MS and 23 healthy donors. Subjects with MS fulfilled established diagnostic criteria (McDonald et al., 2001 ). Demographics and magnetic resonance imaging data for subjects with MS are given in Table 1 . Subjects with MS and healthy donors were matched for age (37 +/− 7 vs. 37 +/− 13 years), gender (male to female ratio: 0.92 vs. 0.88), and included two African American subjects in each group. All subjects provided written, informed consent as part of a research protocol reviewed and approved by an NIH Clinical Center Institutional Review Board. PBMC were isolated by centrifugation of blood samples over Ficoll-Hypaque gradients (Lonza, Walkersville, MD). The cells were viably cryopreserved prior to testing. Purified CD4 + T cells were isolated from PBMC using the Human CD4 + T cell Isolation Kit II (Miltenyi, Auburn, CA) according to the manufacturer's guidelines. Purity of negatively selected CD4 + cells was verified by flow cytometry and was consistently above 93%.
RT-PCR
Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's guidelines and cDNA Journal of Neuroimmunology 230 (2011) 164-168 
